Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Interesting Tlb, thanks. would be good to see the substance if anyone can access it.for transparency's sake i sold out at beginning of the week after holding in various forms since dec 2019,as i was concerned at the poor response to the recent news developments. we have moved from the regulatory risk area to the purely commercial (i have little doubt FUM will be successful in the patent extension) and i find the commercial prospects very difficult to evaluate. im no particular fan of IC and its recommendations, but would be interested to see what slant it puts on the prospects.
Posted on advfn, not seen it myself, Futura buy recommendation in yesterdays issue.
Hi All
Remember it's all about the revenue now! Yes it's a massive market, but Eroxon at present is not a known brand in most part. I'm sorry to keep saying this, but it's all about time, it will be a slow burn. The brand has to build. IMO the US market should hopefully be the catalyst provided they market correctly. But lets face it Haleon are a major player & will get this to market quickly & hopefully if you look at the UK sales the US will be 10x 20x & beyond. I believe at some point we will see a burst in SP then a levelling out & steady rise over months, years. Hold tough. Enjoy the weekend! X
Apologies, I misunderstood your point.
It's all in the detail really. But I maintain they won't have given it all away for very little return. It'll have to be a deal that works well for both.
El_F - No. Revenue from royalties......Keeps the dream alive.
Yes, the market is massive and revenues will be generated - who will be the significant beneficiary?
So you think the royalty payments are worth nothing?
I doubt they would have signed that agreement.
This company has a relatively low MCap, a viable product and a massive market. If it keeps the product IP, it will generate sales revenue for the foreseeable. If they sell the IP or the company, it will be for a decent price, because of the long term value. Of course all in my opinion, but to disregard the royalties is a little short sighted.
Not sure whether some on this (or other) BB,s fully understand the fundamental concept of investing.
"an initial upfront payment of $4 million;"
".....milestone payments totaling between $5 million and $45 million payable over the course of several years".
Realistically, Optimistically, £49 million revenue over several years, from biggest market region in the world.......and the unknown: Revenue from royalties......Keeps the dream alive.
That's the potential.
Partners do the heavy lifting and are remunerated appropriately with a significant slice of the pie.
It’s itching to go..
Wish they hadn't used the term " cutting edge" for something that's rubbed into your member.
At the current SP surely some of the big players in the ED market will be considering whether it would be cheaper long term to just buy FUM or carry out an aggression stock buy up? Which is why I’m shocked at the SP considering many small AIM companies SP’s rocket with just a sniff of potential profits from products that are in development and not actually on the market! IMO some strange things are happening with this stock, & let’s remember they have other products in the pipeline.
Https://naomedical.com/
https://naomedical.com/info/eroxon-gel-revolutionary-solution-erectile-dysfunction.html
Getting Haleon on board is a massive boost to Futura’s hopes for the product, which it reckons has the potential to make sales of up to $1 billion a year if it can carve out a niche in the market.
Lol.. sorry guys wrong posting board. But same goes here soon.
You couldnt make this up.....
Zoomydoo, why would goods news cause rift between members of the management? lol
The rns says “planned transition “
I bloomin hope so Surf but what makes you think that? This has got to be the most frustrating share that I'm in, it should be flying but each bit of good news barely moves the S.P.
Tomorrow could be a good day…
Selling stopped? SP will rise…
Lombards just INCREASED their holding through a warrants exercise in the 40s, an extremely bullish move considering they have indeed sold down some prominent positions recently like NANO.
Good interview. He's clearly dead chuffed, and although there is more detail needed, they've made a very sensible commercial decision here. Shame the share price hasn't stayed up, but that's the way of things these days. Long term I don't see why this won't increase.
Https://finance.yahoo.com/news/futura-medical-absolutely-delighted-us-145230317.html
Looks like getting ready for US sales, does not make sense with market up and this news shares are down but I in for the long game so not bothered.
Lol
Thank you for pointing out I was typing on a mobile phone with no spectacles on, I will be forever grateful for that
Just found this 4min video on YouTube.
I'm unable to translate it all, but it talks alot about Eroxon gel arrival in Brazil.
Almost 400k views in 2 weeks!!!
I hope Boots sales will seem like small change by 2024.
https://youtu.be/ITqS6r3ObSE
Each share has a ‘tape’ to provide real time visibility of trades and their execution prices. There is sometimes a delay in the reporting of some trades, especially those way above normal market size. Investors rely on the tape rather than any backward looking (and possibly delayed for weeks) notification of holdings by buyers or sellers. Claiming something isn’t happening simply because it hasn’t yet been reported by the buyer or seller isn’t a smart way to trade.
Selling on the share tape of Futura is heavily influenced by AT trades. It’s glaringly obvious. Check the clustering and frequency of 10,000 lots, so there’s also a clear element of programme trading, with the trades happening at the same time. When liquidity is weak (not much buy volume on the order book), a sudden flurry of AT sells can suddenly crater the share price, which is what happened on Friday, for example. It can happen any time liquidity on the other side of the market is weak.
There’s no other shareholder with the firepower to consistently be selling on the order book at this frequency and length of time than Lombard. Between 15/12/22 and 24/04/23, it sold almost 3m shares. Futura is a company whose 90 day average trading volume is (according to Morningstar) 1.25m, so finding enough buyers for 3m shares (when there are other, smaller, shareholders also looking to sell) means stretching the sales exercise over a lengthy period, and using high volume days like yesterday to undertake the major work.
We can only hope Lombard gets to its target shareholding soon, but whenever it does, the drag on the share at this price level will stop, and trading rebalance in favour of buys, which will help the share price close its discount to valuation.